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Abstract
Acquisition of an invasive phenotype by cancer cells is a requirement for bone metastasis. Transformed epithe-
lial cells can switch to a motile, mesenchymal phenotype by epithelial-mesenchymal transition (EMT). Recently,
it has been shown that EMT is functionally linked to prostate cancer stem cells, which are not only critically in-
volved in prostate cancer maintenance but also in bone metastasis. We showed that treatment with the non-
peptide αv-integrin antagonist GLPG0187 dose-dependently increased the E-cadherin/vimentin ratio, rendering
the cells a more epithelial, sessile phenotype. In addition, GLPG0187 dose-dependently diminished the size of
the aldehyde dehydrogenase high subpopulation of prostate cancer cells, suggesting that αv-integrin plays an im-
portant role in maintaining the prostate cancer stem/progenitor pool. Our data show that GLPG0187 is a potent
inhibitor of osteoclastic bone resorption and angiogenesis in vitro and in vivo. Real-time bioluminescent imaging in
preclinical models of prostate cancer demonstrated that blocking αv-integrins by GLPG0187 markedly reduced
their metastatic tumor growth according to preventive and curative protocols. Bone tumor burden was signifi-
cantly lower in the preventive protocol. In addition, the number of bone metastases/mouse was significantly in-
hibited. In the curative protocol, the progression of bone metastases and the formation of new bone metastases
during the treatment period was significantly inhibited. In conclusion, we demonstrate that targeting of integrins
by GLPG0187 can inhibit the de novo formation and progression of bone metastases in prostate cancer by anti-
tumor (including inhibition of EMT and the size of the prostate cancer stem cell population), antiresorptive, and
antiangiogenic mechanisms.
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Introduction
Prostate cancer is the most commonly diagnosed malignancy in
many western countries and the second leading cause of cancer death
in male [1]. Because of the progress made in the diagnosis and treat-
ment of primary prostate cancer, mortality in 70% to 80% of the
patients is increasingly linked to metastatic disease, often occult at
time of diagnosis or surgery. The bone marrow is the most frequent
metastatic site for prostate cancer, and colonization of bone marrow
is a critical step in the formation of these bone metastases.
Acquisition of an invasive phenotype of cancer cells in the primary
tumor is a requirement for bone metastasis. Transformed epithelial cells
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can switch from a sessile, epithelial to a motile, mesenchymal pheno-
type by epithelial-mesenchymal transition (EMT) [2]. It has been
shown that EMT may generate cells with properties of stem cells
in human breast and prostate cancer [2,3].
Recently, we found that stem/progenitor cells, besides their role in
tumorigenicity, are highly migratory cells that are involved in bone
metastasis formation [4,5]. Micrometastases are initially formed in
perivascular niches of the bone marrow sinusoids (unpublished ob-
servations). Subsequent outgrowth to clinically overt bone metastases
requires multiple tumor-stroma interactions including angiogenesis
and bone resorption [6,7]. Despite the predominant osteoblastic
phenotype of bone metastases from prostate cancer, tumor-induced
osteoclastic bone destruction is strongly elevated. A multitude of these
functions, including bone homing by cancer cells, tumor-induced
angiogenesis, and osteoclastic bone resorption, are dependent on ad-
hesion receptors of the integrin family, particularly αv-integrins [8–
10]. Integrins are cell surface receptors for extracellular matrix proteins
that play a key role in a variety of biologic activities including signal
transduction, cell adhesion, cell survival, proliferation, migration an-
giogenesis, and gene expression [6,11–13]. Integrins are heterodimers
consisting of an α- and β-subunit, each combination having its own
binding specificity and signaling properties.
Prostate cancer growth is correlated with specific expression and
deregulation of several integrin subunits [6,14–17]. The expression
of αvβ3 integrin in advanced prostate cancer is upregulated compared
to normal prostate tissue, and prostate cancer cells contain a func-
tional αvβ3 integrin [18,19]. As we have recently shown, the expres-
sion of αv-integrin is upregulated in human prostate cancer cells
with tumor- and metastasis-initiating properties [4]. In addition,
αv-integrins are upregulated in a prostate cancer stem cell population
(CD133+, CD44+, and α2β1
hi) compared with the committed pro-
genitor subpopulation [20].
Previous studies using RGD recognition (i.e., using RGD pep-
tides), inhibitory antibodies, or siRNA to block integrins have shown
encouraging results [21–23]. For example, administration of human
αv-siRNA significantly inhibited the growth of human prostate can-
cer xenografts in bone and increased apoptosis of the tumor cells
[23]. Expression of a fully functional αvβ3 integrin enabled tumor
growth in bone, whereas inactive or constitutively active mutants
did not [24]. These data suggest that αvβ3 integrin modulates pros-
tate cancer growth in bone.
In addition, αv as well as α5-integrins play a pivotal role in the
supportive stroma in bone metastasis, particularly in tumor-induced
osteoclastic bone resorption and angiogenesis [10,25–29]. For ex-
ample, Mahabeleshwar et al. [30] showed that vascular endothelial
growth factor–stimulated angiogenesis is reduced in β3-deficient
mice compared to wild type, which resulted in smaller prostate
tumors. Antiangiogenic agents such as JF-10-81, a camptothecin
conjugate, reduced the expression of αvβ3 and αvβ5 in PC3 cells
and blocked tumor cell adhesion and angiogenesis in vivo [31]. Treat-
ment of PC-3 xenografts with an RGD mimetic (S247) resulted in
both antitumor and antiangiogenic effects. Combination with radia-
tion significantly augmented these effects compared to either therapy
alone [32].
Taken together, inhibiting αv-integrin function seems a promising
strategy to prevent prostate cancer progression at various stages.
In this article, we evaluated the efficacy of GLPG0187, a nonpep-
tide RGD antagonist on prostate cancer growth in preclinical models
of prostate cancer metastasis. We demonstrate that targeting of the
αvβ3 integrins by GLPG0187 can inhibit both de novo formation
as well as progression of bone metastases in prostate cancer.
Materials and Methods
Cell Culture
Human prostate cancer PC-3M-Pro4/luc+ cells were maintained in
Dulbeccomodified Eaglemedium (GibcoBRL, Breda, TheNetherlands)
containing 4.5 g glucose/L supplemented with 10% FCII, 100 U/ml
penicillin, 50 μg/ml streptomycin, and 800 μg/ml geneticin/G418
(Invitrogen, Breda, The Netherlands) as described previously [33] (see
Supplementary Methods). Cells were regularly monitored and were
certified free of mycoplasma contamination.
Osteoclastogenesis Assay
Murine bone marrow cells were cultured in α-minimum essential me-
dium containing 10%heat-inactivated fetal bovine serum in the presence
of RANKL (PeproTech, Neuilly-sur Seine, France; 6 ng/ml) and mem-
brane form of macrophage colony-stimulating factor (R&D Systems,
Oxford, UK; 25 ng/ml) in 96-well tissue culture plates [34]. Cells were
fixed and stained for tartrate-resistant acid phosphatase (TRAcP) activity
after 5 days in culture, using a commercial kit (387-A; Sigma-Aldrich,
St Louis, MO).
Migration Assay
Migration was performed in 8-μm Transwell migration chambers
(Costar, Amsterdam, The Netherlands). A total of 6 × 104 prestarved
(0.1% fetal calf serum) PC-3M-Pro4/luc cells were seeded in the upper
chamber containing either vehicle or GLPG0187 compound and al-
lowed to migrate toward serum-containing medium in the lower cham-
ber. Cells were fixed after 6 hours with 4% paraformaldehyde and
stained with 0.1% crystal violet (2 mg/ml; Sigma-Aldrich, The Nether-
lands). Three random fields were counted for each well, and mean
numbers of migrated cells/field were calculated [35].
Fluorescence-Activated Cell Sorter
PC-3M-Pro4/luc cells were harvested and labeled with E-cadherin–
FITC (BD Biosciences 1:10 in FACS buffer: PBS with 0.1% sodium
azide and 1% fetal calf serum) for 30 minutes at 4°C in the dark.
Then, cells were washed with 1 ml of FACS buffer and fixed with
freshly prepared 2% formaldehyde for 15 minutes. Cells were washed
with ice-cold PBS and subsequently incubated for 30 minutes at 4°C
in the dark with vimentin rabbit polyclonal antibody (1:200 in FACS
buffer; AbCaM, Cambridge, UK). Cells were washed twice with 1 ml
of FACS buffer and incubated with goat–anti rabbit IgG-APC (Invitro-
gen). After washing, samples were analyzed using the Becton Dickinson
FACSCalibur2 (Breda, The Netherlands) and FCS express software
(De Novo Software, Los Angeles, CA). Aldehyde dehydrogenase
(ALDH) activity was measured as described earlier [4].
RNA Isolation and Real-time Quantitative Polymerase
Chain Reaction
RNA was extracted using TRIzol (Invitrogen) according to the
manufacturer’s instructions. Real-time quantitative polymerase chain
reaction (qPCR) was run and analyzed with a Bio-Rad iQ5 Cycler
(Bio-Rad, Veenendaal, The Netherlands). For primer sequences, see
Table W1. Gene expression was measured relative to GAPDH expres-
sion using the following formula: log2−ΔΔCt [36].
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Angiogenesis Assays
Metatarsal angiogenesis assay. Seventeen-day-old fetuses were re-
moved from pregnant Swiss albino mice, and metatarsals were dis-
sected as described previously [37]. The isolated metatarsals were
cultured for 10 days in 24-well plates in the presence of vehicle
(1:1 dimethyl sulfoxide/PBS) or different concentrations ofGLPG0187.
Subsequently, the metatarsals were fixed and stained for platelet/
endothelial cell adhesion molecule 1 (CD31) as described previously
[37]. The experiment was performed three times with eight cultures
per condition.
Neonatal Tail Angiogenesis Assay
The neonatal mouse tail provides a suitable model to simulta-
neously assess bone angiogenesis and osteoclastogenesis in vivo [37].
Two-day-old neonatal Swiss albino mice were subcutaneously treated
with GLPG0187 (30 mg/kg per day) or vehicle (1:1 dimethyl sul-
foxide in PBS) for four consecutive days, starting at the second day
after birth (n = 4). After 4 days of treatment the animals were killed,
and the tails were stained for lectin and for osteoclasts (TRAcP stain-
ing) [37].
Xenograft Experiments
Mouse strain. Male nude mice (BALB/c nu/nu; Charles River,
L’Arbresle, France) were housed in individual ventilated cages under
sterile condition according to the Dutch guidelines for the care and
use of laboratory animals (DEC 4077). Before surgical and analytical
procedures were performed, the mice were anesthetized.
Intracardiac inoculation of PC-3M-Pro4/luc cells to induce sys-
temic metastases. A single-cell suspension of 1 × 105 PC-3M-
Pro4/luc cells/100 μl PBS was injected into the left cardiac ventricle
of 4-week-old nude mice as described previously [33]. The progres-
sion of cancer cell growth was monitored weekly by bioluminescent
imaging (BLI) using the IVIS100 Imaging System (Caliper Life-
Sciences, Hopkinton, MA) [33]. Analyses for each metastatic site were
performed after definition of the region of interest and quantified with
Living Image (Caliper LifeSciences). Values are expressed as relative
light units.
Histomorphometry, histochemistry, and immunohistochemistry.
Dissected tissues from animal studies were fixed in 4% paraformal-
dehyde (pH 6.8), decalcified (only bones) as described previously and
processed for paraffin embedding, sectioning, and staining [4,37].
Statistical Analysis
Data are presented as mean ± SEM. Two-way analysis of variance
was performed followed by the post hoc Bonferroni test. P < .05 was
considered to be significant (*P < .05, **P < .01, ***P < .001).
Results
GLPG0187 and Cellular Characteristics of PC-3M-Pro4
Prostate Cancer Cells
Bone homing of cancer cells, tumor-induced angiogenesis, and os-
teoclastic bone resorption are dependent on adhesion receptors of the
integrin family, particularly αv-integrins. Tumor-initiating cells have
recently been identified in many solid tumors, including breast and
prostate. Evidence is mounting that tumor-initiating cells are not
only critically involved in cancer initiation and progression but also
in colonization and bone metastasis formation [4,5,38–40]. Strik-
ingly, αv-integrin expression is associated with the basal layer of the
human prostate and its expression is also upregulated in tumor-
initiating cells (Figure W1A; source: www.proteinatlas.org) [4,20].
The prostate cancer cell line PC-3 and its derivative PC-3M-Pro4/
luc displayed high levels of αv-integrin as detected by immunohisto-
chemistry and flow cytometry (99.7% of the cells express αv-integrin;
Figure W1, A and B). Furthermore, αv integrins are highly expressed
in osteoclasts and activated endothelial cells where they play functional
roles related to bone resorption and angiogenesis, respectively [41,42].
In the present study, we investigated the effects of blocking αv-
integrin on prostate cancer growth and bone metastasis. The non-
peptide RGD integrin receptor antagonist, GLPG0187, blocks six
integrin receptors and displays a unique anti-integrin profile in solid-
phase integrin-ligand binding assays (see Supplementary Methods).
In a solid-phase assay, GLPG0187 showed selectivity for several
RGD integrin receptors with the following IC50: 1.3 nM for αVβ1,
3.7 nM for αVβ3, 2.0 nM for αVβ5, 1.4 nM for αVβ6, 1.2 nM for
αVβ8, and 7.7 nM for α5β1. It is important to note that GLPG0187
has poor affinity (IC50 > 10 μM) for the platelet-specific integrin re-
ceptor integrin-αIIβ [43].
Effect of GLPG0187 on Osteoclastogenesis In Vitro and
In Vivo
To determine whether GLPG0187 displayed effects on the sup-
portive tumor stroma, first the effects of GLPG0187 on osteoclasto-
genesis were assessed (schematic representation; Figure 1A) [44].
During osteoclast differentiation, podosomes are found as compo-
nents of larger structures known as clusters, rings, or belts. As shown
in Figure 1B, osteoclasts can be subdivided into three different cate-
gories: moving, sitting, and rings according to their morphology
(shown by light microscopy and actin staining). GLPG0187 signifi-
cantly decreased the amount of osteoclasts forming a ring, a structure
necessary for osteoclastic resorption (Figure 1C ).
Osteoclastogenesis induced by RANKL and mM-CSF from mice
bone marrow osteoclast precursors was inhibited by GLPG0187
(0.39–200 nM), with a statistically significant effect at concentra-
tions ≥3 nM (Figure 1D).
In orchidectomized (ORX) rodents, increased bone resorption due
to an imbalance in osteoblastic and osteoclastic activity, results in a
significantly reduced trabecular bone volume (BV/TV) and bone
mineral density (BMD) in the proximal tibia metaphysis.
ORX mice were treated with GLPG0187, immediately after castra-
tion, either by subcutaneous route at the doses of 10, 30, or 100 mg/kg
(twice a day) or orally at the doses of 30, 100, or 300 mg/kg (twice
a day). In line with the efficacy of GLPG0187 to inhibit osteoclast
formation and osteoclastic bone resorption, with either route of ad-
ministration, GLPG0187 significantly and dose-dependently pre-
vented ORX-induced bone loss (Figure W2).
Effect of GLPG0187 on Angiogenesis In Vitro and In Vivo
Subsequently, the effect of GLPG0187 on angiogenesis was eval-
uated using in vitro and in vivo models [37]. Continuous treatment
of 17-day-old fetal murine metatarsals for 10 days with various doses
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of GLPG0187 prevented the outgrowth of CD31-positive capillary
structures in a dose-dependent manner (Figure 2, A and B).
Next, we evaluated the effects of GLPG0187 in an in vivo model
of endochondral bone formation that can be exploited to simulta-
neously assess the formation of capillaries and osteoclasts. At the start
of the experiment (day 2 postpartum), the 28 caudal vertebrae of the
mouse-tail encompass different developmental regions [37]. From
proximal to distal, vertebrae are composed of developing trabecular
bone with a primitive bone marrow cavity (vertebrae 1-10), calcified
avascular cartilage (vertebrae 11-21), and nonmineralized avascular
cartilage (vertebrae 22-28). The invasion front was determined as
the first sign of vascular invasion and/or osteoclast invasion of a
developing caudal vertebra (Figure 2C ). After 4 days of vehicle treat-
ment, the invasion front progressed to the distal end and was located
at approximately vertebra 20 (Figure 2C ). In line with our in vitro
observations, administration of GLPG0187 resulted in a significant
delay in both invasion of the caudal vertebrae by osteoclasts and
blood vessels (at V20 [capillaries] and V21 [osteoclasts], respectively,
under control conditions and at V14 [capillaries] and V15 [osteo-
clasts], respectively, in the GLPG0187-treated animals) (Figure 2,
E–G ). Taken together, our data show that GLPG0187 is a potent
inhibitor of angiogenesis both in vitro and in vivo.
Direct Effects on Tumor Cells of GLPG0187
In addition to the effects on the supportive stroma, we investigated
whether GLPG0187 displayed direct effects on the tumor cells. Treat-
ment of PC-3M-Pro4/luc prostate cancer cells with GLPG0187 re-
sulted in a dose-dependent decrease in adhesion to tissue culture
plastic as prostate cancer cells started to grow in suspension from 4 hours
onward (the effect after 24 hours of treatment with GLPG0187 is seen
in Figure W3A). This was not due to the altered viability of the treated
PC-3M-Pro4/luc cells because no significant differences in cell death
were found with an annexin V/PI apoptosis assay (Figure W3B). More-
over, the proliferation rate of PC-3M-Pro4/luc cells after 48 and 72 hours
of treatment was significantly decreased (Figure W3C).
Acquisition of an invasive phenotype is a requirement for bone metas-
tasis; transformed epithelial cells can switch to a motile, mesenchymal
phenotype by EMT. GLPG0187 dose-dependently and significantly
increased the E-cadherin/vimentin ratio in PC-3M-Pro4/luc cells, indi-
cative of a less invasive and more epithelial phenotype (Figure 3A). On
Figure 1. GLPG0187 affects osteoclastogenesis. (A) Schematic representation of osteoclast formation in an osteoclast model adapted
from Jurdic et al. [44]. (B) Representative images of light microscopy and fluorescent actin staining showing the different morphology of
differentiating osteoclasts. (C) Effect of GLPG0187 on the amount of osteoclasts in each differentiation morphology. (D) Bone marrow
cells isolated from 8-week-old female mice tibiae and femora were cultured during 5 days in the presence of RANKL and mM-CSF and
of various concentrations of GLPG0187. TRAcP activity was measured using densitometry. Data are expressed as mean ± SEM (n = 4).
*P < .05 versus stimulated control.
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Figure 2. GLPG0187 inhibits angiogenesis both in vitro and in vivo. (A) Total area of CD31-positive capillary-like structures was deter-
mined by computerized image analysis in 17-day-old fetal mouse metatarsals treated for 10 days with either vehicle or GLPG0187. Data
are expressed as percent of control ± SEM. (B) Representative images of control and 10 nM GLPG0187-treated metatarsals. Schematic
representation of angiogenesis and accession to calcified cartilage of osteoclasts (adhesion to bone, migration on bone surface, and
bone resorption) in the caudal vertebrae in neonatal mouse-tails under control conditions (vehicle) (C) or GLPG0187-treated conditions
(D). Tails were processed and double-stained for TRAcP (red) and lectin (brown). At day 2 postpartum (p.p.), osteoclast-precursors and
blood capillaries have started to invade the bone collar at caudal vertebrae 11 and 10, respectively. Four days later, osteoclast-precursors
and capillaries have progressed in a distal manner, and their invasion fronts can now be identified at V20 (capillaries) and V21 (osteo-
clasts) under control conditions and at V14 (capillaries) and V15 (osteoclasts) in the GLPG0187-treated animals. n = 4 mice/group. Rep-
resentative images of vertebrae 13 of vehicle treated (E) or GLPG0187-treated animals (F and G) are shown. BM indicates bone marrow;
BV, blood vessels; HC, calcified cartilage; OC, osteoclast.
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treatment, the messenger RNA levels of the prometastatic regulators
Twist, Snail1, and Snail2 decreased as measured with real-time qPCR
(Figure 3B).
Migration of PC-3M-Pro4/luc cells in a Transwell Boyden cham-
ber was significantly and dose-dependently blocked by GLPG0187
(Figure 3C ).
Recently, our group showed that high aldehyde dehydrogenase
(ALDHhi) activity can be used to identify prostate cancer cells with
tumor-initiating and metastasis-initiating ability [4]. When treated
with GLPG0187, the size of the ALDHhi cells’ subpopulation of
cancer stem/progenitor cells decreased significantly (Figure 3D).
Treatment of human C4-2B prostate cancer cells with GLPG0187
revealed similar effects, that is, dose-dependent loss of adhesion to
tissue culture plastic (Figure W5A) and dose-dependently increased
E-cadherin/vimentin ratio (Figure W5B). In addition, GLPG0187
dose-dependently diminished the size of the ALDHhi subpopulation
of prostate cancer cells (Figure W5C ). Migration of C4-2B cells was
also dose-dependently decreased by GLPG0187 (Figure W5D).
Taken together, these data show that GLPG0187 dose-dependently
inhibits EMT and migration and decreases the percentage of prostate
cancer cells with tumor-initiating and metastasis-initiating ability.
GLPG0187 and Prostate Cancer Bone Metastasis
Subsequently, we investigated whether blocking αv-integrin can be
used to treat experimentally induced bone metastasis from human
prostate cancer cells (PC-3M-Pro4/luc) according to a preventive
protocol using bioluminescent imaging (Figure 4A). Total tumor
burden was significantly and dose-dependently decreased in mice
subcutaneously treated with GLPG0187 (Figure 4, B-D). Bone tu-
mor burden was approximately 1000 times lower in the 100-mg/kg
per day GLPG0187 group versus vehicle in the preventive protocol
(Figure 4E ). In addition, the number of bone metastases/mouse
was significantly inhibited (Figure 4F ).
In the curative protocol, bone metastases were allowed to develop
for 21 days (Figure 5A). Subsequently, the mice were treated with
an oral dosage of either vehicle or GLPG0187 (30 or 100 mg/kg
per day) to investigate whether blocking αv-integrin can be used
to treat already-existing bone metastases. Total tumor burden was
significantly decreased after 15 days of treatment with 30-mg/kg
per day GLPG0187 (Figure 5, B and C ). In addition, the progres-
sion of bone metastases was significantly inhibited on treatment
from 12 days onward with both the 30- and 100-mg/kg per day
GLPG0187 groups (Figure 5D). Importantly, the formation of new
bone metastases during the treatment period was strongly inhibited
in both 30- and 100-mg/kg per day GLPG0187 groups (Figure 5E).
Similar data were obtained in another curative protocol using twice-daily
subcutaneous administration of GLPG0187 (Figure W4). GLPG0187
showed significant and dose-dependent bone-sparing effects compara-
ble to the bisphosphonate zolendronate as shown in Figure 5F.
Discussion
The bone marrow is the most frequent metastatic site for prostate
cancer, and colonization of the bone marrow is a critical step in the
formation of bone metastasis.
Figure 3. Effect of GLPG0187 on EMT, migration, and percentage of ALDHhi stem/progenitor cells. Cells were treated for 48 hours with a
concentration range of GLPG0187, and subsequently, relative E-cadherin/vimentin ratio (A) was measured with flow cytometry and lev-
els of EMT inducers including Snail1 and 2 and Twist were measured with real time qPCR (B). Data are represented as log fold change
(log2−ΔΔCt). Mean numbers of migrated PC-3M-Pro4/luc cells per field were measured (C). Data are presented as mean ± SEM (*P <
.05) and are representative for three independent experiments. Percentage of PC-3M-Pro4/luc cells with high ALDH activity as measured
with ALDEFLUOR assay (D) [4].
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Integrins mediate several important processes including tumor-
induced angiogenesis, tumor-induced osteoclastic bone resorption,
cancer cell invasiveness, thus providing the rationale for the use of
integrin inhibitors in metastatic bone disease [8–10].
It has been shown previously that αvβ3 integrin plays a crucial role
in the osteotropism of various carcinomas [24,45,46]. These data
have identified αvβ3 integrin as a potential therapeutic target for
the treatment of bone metastases.
Acquisition of an invasive phenotype is a critical step in the for-
mation of bone metastases. Transformed sessile, epithelial cells can
switch to a motile mesenchymal phenotype by the process of EMT.
During EMT, epithelial characteristics are shed, and cancer cells
acquire a more mesenchymal motile cell phenotype, coinciding with
increased αv integrin expression [2]. We show that administration of
GLPG0187 significantly and dose-dependently decreased adhesion
and the migratory ability of human prostate cancer cells in vitro. In
addition, treatment with an αv inhibitor dose-dependently induced a
more sessile epithelial phenotype as observed by increased E-cadherin/
vimentin ratios. These data are further substantiated by a dose-dependent
decrease in the expression of E-cadherin suppressors Snail1, Snail2
(formerly known as Slug), and Twist [47].
Transforming growth factor β (TGFβ) is a major EMT effector in
transformed cells and is a key factor in tumor progression and bone
metastasis [48]. Interestingly, extensive crosstalk exists between in-
tegrins and TGFβ. TGFβ is secreted in an inactive, latent form in
a complex with TGFβ latent binding proteins [49]. Dissociation of
the complex by binding of integrins to the RGD motif in the TGFβ
latent binding protein can activate TGFβ. In addition, TGFβ can
induce the expression of several integrins, thereby enhancing the
migratory and invasive behavior of cancer cells [49]. Interfering with
the self-amplifying, TGFβ-driven tumor-stroma interactions, critical
for tumor invasiveness and metastasis, therefore provides the ratio-
nale for the use of αv antagonists. Interestingly, it has been shown
that TGFβ plays a key role in the formation of the mammary epi-
thelial stem cell pool in breast cancer, mediated by EMT [39,40].
Furthermore, recent evidence suggests that EMT is mechanistically
Figure 4. Effects of systemic administration of GLPG0187 on tumor growth and formation of de novo metastases. (A) Schematic
representation of the preventive protocol. Mice were treated daily with either subcutaneously administrated vehicle or GLPG0187 from
day −1 onward. At day 0, 100,000 PC-3M-Pro4/luc cells were inoculated into the left heart ventricle, and once a week, body weight
was measured and BLI images were taken. (B) Representative images of mice treated with vehicle or 100 mg/kg per day GLPG0187
taken at day 28 after inoculation. (C) Total tumor burden for the mice treated with 30 mg/kg per day GLPG0187 (closed triangles),
100 mg/kg per day GLPG0187 (closed circles), or vehicle (open circles). (D) Dose-dependent reduction in tumor volume in GLPG0187-
treated animals as shown by hematoxylin and eosin staining (bone images of vehicle, 30-mg/kg per day, and 100-mg/kg per day
GLPG0187-treated animals, respectively). (E) Bone tumor burden for the mice treated with 30-mg/kg per day GLPG0187 (closed triangles),
100-mg/kg per day GLPG0187 (closed circles), or vehicle (open circles). (F) Total number of bone metastases per mouse (n = 10/group;
*P < .05).
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linked to the formation of highly tumorigenic prostate cancer stem/
progenitor cells with a mesenchymal, migratory, clonogenic phenotype
[3]. EMT may therefore generate cells with properties of stem cells,
which are critically involved not only in tumor initiation and pro-
gression but also in colonization and bone metastasis formation [3–
5,38–40]. Recently, we found that ALDHhi activity can be used to
identify prostate cancer cells with increased tumor-initiating and
metastasis-initiating ability [4]. Interestingly, the level of αv-integrin
was significantly increased in ALDHhi cancer cells compared to the
ALDHlow prostate cancer cells [4]. Inhibitingαv-integrinwithGLPG0187
dose-dependently inhibited the percentage of ALDHhi cells in prostate
cancer cell lines, suggesting that αv-integrin plays an important role in
maintaining the prostate cancer stem/progenitor pool. Our observations
are in linewith data showing a high expression ofαv-integrin in the pros-
tate basal layer compared to more differentiated counterparts [20].
Besides the direct effects of inhibiting αv-integrin on the tumor
cells, GLPG0187 also affected the tumor microenvironment, in
particular angiogenesis and osteoclastic bone resorption. Similar to
Figure 5. Effects of systemic administration (orally) of GLPG0187 on tumor growth of established bone metastases. (A) Schematic
representation of the curative protocol. At day −21, 100,000 PC-3M-Pro4/luc cells were injected into the left heart ventricle, and once
a week, body weight was measured, and BLI images were taken. At day 0, mice were divided into groups with equal total tumor burden.
Mice were daily treated with an oral dosage of either vehicle or GLPG0187 from day 0 onward. (B) Representative images of mice
treated with vehicle or 30-mg/kg per day GLPG0187 taken at day 15 after start of treatment. (C) Total tumor burden for the mice treated
with 30-mg/kg per day GLPG0187 (closed triangles), 100-mg/kg per day GLPG0187 (closed circles), or vehicle (open circles). (D) Bone
tumor burden for the mice treated with 30-mg/kg per day GLPG0187 (closed triangles), 100-mg/kg per day GLPG0187 (closed circles), or
vehicle (open circles). (E) Total number of bone metastases per mouse (n = 10/group; *P < .05). (F) Ratio of bone volume (BV) over total
volume (TV) of mice injected with either vehicle, GLPG0187, or zoledronate (10 μg/kg per day) at day 15 after start of treatment as
measured with micro-CT scanning (Micro-densitometer Scanco μCT20).
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invasive cancer cells, activated endothelial cells depend on αv integrins
for de novo formation of capillaries from preexisting blood vessels.
GLPG0187 significantly and dose-dependently inhibited angiogenesis
both in in vitro and in vivo angiogenesis assays.
Administration of GLPG0187 reduced osteoclastogenesis and
bone resorption both in vitro and in vivo. The levels of inhibition
were comparable to the bisphosphonate zolendronate [41].
In a preventive study, GLPG0187 could inhibit bone metastases
formation and dose-dependently inhibited tumor burden. Moreover,
oral or subcutaneous administration of GLPG0187 could block the
progression of already existing bone metastases and prevent de novo
formation of metastases in a curative protocol. Our observations are
in line with administration of an αv integrin antagonist in breast can-
cer cells, which resulted in decreased tumor growth and bone metas-
tasis in preclinical models of breast cancer [46].
In conclusion, both our in vitro data and our preclinical mod-
els show that administration of GLPG0187 inhibits multiple pro-
cesses along the bone metastatic cascade. Targeting of integrins by
GLPG0187 can inhibit the de novo formation and progression of
bone metastases in prostate cancer by antitumor (including inhi-
bition of EMT and the size of the prostate cancer stem/progenitor
cell population), antiresorptive, and antiangiogenic mechanisms.
GLPG0187 can therefore potentially be used to treat bone metasta-
ses in prostate cancer.
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Supplementary Methods
Cell Culture
The human osteotropic PC-3M-Pro4 prostate cancer cells were
generated from PC-3 cells (ATCC no. CRL-1435) by injecting
PC-3 cells into athymic mouse prostates and selecting for clones with
increasing metastatic potential by several rounds of reinjecting cells
from xenograft tumors back into the mouse prostate. PC-3M-Pro4
cells were stably transfected with a CMV promoter–driven mam-
malian expression vector containing firefly-luciferase (pcDNA3.1
CMV-ff-luc). One clone with high luciferase activity was selected
with neomycin (800 μg/ml; Life Technologies, Basel, Switzerland)
and successfully used for in vivo bioluminescent imaging as described
previously (e.g., Buijs et al. [2007]. Am J Pathol 171, 1047–1057;
and van den Hoogen et al. [2010]. Cancer Res 70, 5163–5173).
The androgen-independent and metastatic C4-2B cells were main-
tained as described previously (Thalmann et al. [2000]. Prostate 44,
91–103).
Proliferation Assay
Cells were seeded at a density of 2500/cm2 and allowed to grow
overnight before treatment and then for an additional 1 to 3 days.
Twenty microliters of MTS was added to the medium, and mitochon-
drial activity was measured at 490 nm after 2 hours of incubation at
37°C (CellTiter96 AQueous Non-Radioactive Cell proliferation assay;
Promega, Madison, WI).
Apoptosis Assay
For apoptotic analysis, harvested cells were stained with AnnexinV/
PI (Alexa Fluor 488 annexin V/Dead Cell Apoptosis Kit; Invitrogen),
incubated for 15 minutes according to the manufacturer’s protocol.
Samples were analyzed with FACSCalibur2 (Becton Dickinson) and
FCS Express software (De Novo).
Solid-Phase Assays
Integrins. Integrin α2β1 was purified from detergent extracts of
HT1080 fibrosarcoma cells as previously described [1]. Recombinant
integrin α4β7 was purchased from R&D Systems (Oxford, UK). Re-
combinant integrin α5β1 was made as an Fc fusion protein as described
before [2]. Recombinant αv integrins were made using a baculovirus
expression system in insect cells [3]. Note that the recombinant pro-
teins contain the complete extracellular domains of the integrin.
Ligands. Rat tail tendon collagen was obtained from Sigma-Aldrich
(Poole, Dorset, UK) and biotinylated as described [1]. Recombinant
murine MAdCAM-1 Fc fusion protein was made in COS cells [4].
A recombinant fragment of human fibronectin containing type III re-
peats 6 to 10 was produced and biotinylated as described [5]. Purified
human vitronectin was obtained from Sigma-Aldrich. Recombinant
human latency-associated protein was purchased from R&D Systems
and biotinylated using sulfo-NHS-LC-biotin (Pierce, Rockford, IL) ac-
cording to the manufacturer’s protocols.
General assay methods. For solid-phase assays, the binding of li-
gands to integrins was measured in the presence of 1 mM Mn2+ to
activate the receptors. In brief, 96-well plates (Costar 12-area EIA/
RIA; Corning Science Products, High Wycombe, UK) were coated
with integrins (1-5 μg/ml in Dulbecco PBS) overnight at room tem-
perature. Wells were then blocked for 2 hours with 200 μl of
5% (wt/vol) bovine serum albumin (BSA), 150 mM NaCl, 0.05%
(wt/vol) NaN3, and 25 mM Tris-HCl, pH 7.4 (blocking solution).
The blocking solution was removed, and the wells were then washed
three times with 200 μl of 150 mM NaCl, 25 mM Tris-HCl, and
1 mM MnCl2, pH 7.4, containing 1 mg/ml BSA (buffer A). Ligands
in buffer A were added to the wells in the absence or presence of
inhibitors, and the plate was then incubated at room temperature
for 2 hours. Unbound ligand was removed, and the wells were washed
three times with buffer A. For biotinylated ligands, bound ligand was
quantitated by addition of 1:500 dilution of ExtrAvidin peroxidase
conjugate (Sigma-Aldrich) in buffer A for 30 minutes at room temper-
ature (50 μl/well). For MAdCAM-Fc, bound ligand was quantitated
by the addition of 1:1000 dilution of antihuman Fc peroxidase conjugate
(Jackson, Suffolk, UK) 30 minutes at room temperature (50 μl/well).
For vitronectin, bound ligand was quantitated by the addition of 1:500
dilution of antihuman vitronectin antibody VIT-2 (Sigma-Aldrich) for
30 minutes at room temperature followed by 1:1000 dilution of anti-
human IgMperoxidase conjugate (Jackson) for 30minutes at room tem-
perature (50 μl/well). Wells were then washed four times with buffer A,
and color was developed using ABTS substrate (50 μl/well; Pierce).
Measurements obtained were the mean of four replicate wells. Back-
ground binding of ligands to wells coated with BSA alone was subtracted
from all measurements. IC50 = concentration of inhibitor for 50% of
maximal inhibition of ligand binding to the integrin used in the assay
[6]. Data obtained were from a minimum of two experiments (n = 2
or n = 3).
ORX
Study design. The effect of GLPG0187 on bone loss was evaluated
in 3-month-old castrated male mice after 4 weeks of treatment with
dosing starting immediately after castration (preventive protocol).
Two different modes of administration were used: either subcutane-
ous twice daily with 10, 30, or 100 mg/kg of GLPG0187, either oral,
twice daily with 30, 100, or 300 mg/kg of GLPG0187.
Animal housing. Male BALB/c mice used were from Charles River
Laboratories (l’Arbresle, France). Mice were 12 weeks old at the time
of castration and were maintained under controlled and continuously
monitored conditions of temperature (21 ± 2°C), humidity (45% ±
10%), photo period (12:12-hour light-dark), and air exchange. All
animals were maintained on a diet and tap water ad libitum.
Orchidectomy procedure. Mice were injected intraperitoneally (i.p.)
with anesthesia solution 100 μl/100 g BW (Kétamine; ImalgèneR
1000; Merial, Villeurbanne, France). Postoperative care: castrated mice
were maintained in a wakeup room for 2 hours, on a cellulose bed
under a warming lamp before being reinstalled in their homing room.
Bone measurements. Mice tibias were recovered from 16-week-old
mice after sacrifice and were used for tomodensitometric, histomor-
phometric, and densitometric analyses.
Tomodensity. Left tibias were collected, fixed overnight in formalin,
and then stored at 4°C in 70% ethanol for micro-CT scanning. Basic
structural metrics were measured using direct two-dimensional mor-
phometry (Micro-densitometer Scanco μCT20, Software version 1.6
update in 2006; Scanco Medical, Brüttisellen, Switzerland) Micro-CT
scans of the metaphyseal region were performed at an isotropic resolu-
tion of 9 μm to obtain trabecular bone structural parameters. The bone
tissue was segmented from the marrow using a global threshold pro-
cedure. Using a two-dimensional model, bone volume, bone surface,
and the trabecular thickness were determined. Cortical and trabecular
bones were separated using a semiautomated contour-tracking algo-
rithm to detect the outer and inner boundaries of the cortex [7,8].
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Table W1. Real-time qPCR Primers.
Gene 5′ Sequence 3′ Sequence
Twist TGTCCGCGTCCCACTAGC TGTCCATTTTCTCCTTCTCTGGA
Snail1 TGCAGGACTCTAATCCAAGTTTACCC GTGGGATGGCTGCCAGC
Snail2 TGTGTGGACTACCGCTGC TCCGGAAAGAGGAGAGAGG
GAPDH GACAGTCAGCCGCATCTTC GCAACAATATCCACTTTACCAGAG
Exon-spanning real-time PCR primers designed with Primer Express software (Applied Biosystems,
Rotkreuz, Switzerland).
Figure W1. Immunolocalization and expression of αv-integrin in normal prostate, prostate cancer tissue, and prostate cancer cell line. (A)
Tissue sections of normal human prostate (left panel), human prostate carcinoma (middle panel), or the human prostate cancer cell line
PC3 (right panel). Sections were stained with αv-integrin antibody (Novocastra, Leica Microsystems BV, Rijswijk, The Netherlands; data
source: protein atlas www.proteinatlas.org). (B) Dot plot and histogram showing integrin-αv expression in PC-3M-Pro4/luc cells.
Figure W2. Effect of GLPG0187 (subcutaneously or orally) on trabecular bone volume loss in ORX mice assessed on proximal tibia
metaphysis. (A) Three-month-old ORX male mice (n = 8) were treated for 4 weeks either with vehicle or with GLPG0187, with dosing
initiated immediately after ORX. The effects on bone loss were monitored by measuring changes in trabecular bone volume (BV/TV).
Data are expressed as mean ± SEM. ###P < .001 versus ORX mice.
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Figure W3. In vitro effects of GLPG0187 on proliferation and apoptosis. (A) Representative images of PC-3M-Pro4 cells treated with
either vehicle or different concentrations of GLPG0187 for 24 hours. (B) PC-3M-Pro4 cells were seeded into a six-well plate and exposed
to GLPG0187 (0, 1, and 5 ng/ml). At 48 hours after incubation, cells were harvested and processed for annexin V/PI staining with the
Alexa Fluor 488 annexin V/Dead Cell Apoptosis Kit (Invitrogen). The percentage of live (AnnexinV−/PI−), dead (PI+/AnnexinV−), and total
apoptotic cells (AnnexinV+) are shown. (C) Proliferation rate of PC-3M-Pro4/luc cells treated with either vehicle or GLPG0187 for 24, 48,
and 72 hours was assessed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (optical density at 490 nm).
Figure W4. Effects of systemic administration (SC) of GLPG0187 on tumor growth of established (bone) metastases. (A) Schematic
representation of the curative protocol. At day −21, 100,000 PC-3M-Pro4/luc cells were injected into the left heart ventricle, and once
a week, body weight was measured, and BLI images were taken. At day 0, mice were divided into groups with equal total tumor burden.
Mice were daily treated with either vehicle or GLPG0187 from day 0 onward. Representative images of mice treated with either vehicle
(B) or 30-mg/kg per day GLPG0187 (C) taken at day 15 after start of treatment. (D) Ratio of bone volume (BV) over tumor volume (TV) of
mice injected with vehicle, GLPG0187, or zoledronate (10 μg/kg per day) at day 15 of treatment. (E) Bone tumor burden for the mice
treated with 30-mg/kg per day GLPG0187 (closed bars) or vehicle (open bars). (F) Total number of bone metastases per mouse (n = 10/
group; *P < .05).
Figure W5. Effect of GLPG0187 on EMT, migration, and percentage of ALDHhi stem/progenitor cells. (A) Representative images of C4-
2B cells treated with either vehicle or different concentrations of GLPG0187 for 4 hours. (B) C4-2B cells were treated for 48 hours with a
concentration range of GLPG0187, and subsequently, relative E-cadherin/vimentin ratio was measured with flow cytometry. (C) Percent-
age of C4-2B cells with high ALDH activity as measured with ALDEFLUOR assay. (D) Mean numbers of migrated C4-2B cells per field
were measured. Data are presented as mean ± SEM (*P < .05) and are representative for two independent experiments.
Figure W5. (continued).
